Odapipam acetate | CAS# 142382-09-0 | Biochemical

MedKoo Cat#: 578244 | Name: Odapipam acetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Odapipam acetate is a benzazepine with high affinity and selectivity for D1-dopamine receptors.

Chemical Structure

Odapipam acetate

CAS#142382-09-0

Theoretical Analysis

MedKoo Cat#: 578244

Name: Odapipam acetate

CAS#: 142382-09-0

Chemical Formula: C21H24ClNO4

Exact Mass: 389.1394

Molecular Weight: 389.88

Elemental Analysis: C, 64.70; H, 6.21; Cl, 9.09; N, 3.59; O, 16.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

NNC 772; NNC772; NNC-772; Odapipam acetate

IUPAC/Chemical Name

1H-3-Benzazepin-7-ol, 8-chloro-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-, (S)-, acetate (salt)

InChi Key

XWEWSCUVTBLEBS-PKLMIRHRSA-N

InChi Code

InChI=1S/C19H20ClNO2.C2H4O2/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14;1-2(3)4/h2-4,9-10,16,22H,5-8,11H2,1H3;1H3,(H,3,4)/t16-;/m1./s1

SMILES Code

CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c3cccc4CCOc34.CC(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 389.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Andersen JV, Hansen KT. Normal-phase liquid chromatography-particle-beam mass spectrometry in drug metabolism studies of the dopamine receptor antagonist Odapipam and the muscarine M1 receptor agonist Xanomeline. Xenobiotica. 1997 Sep;27(9):901-12. doi: 10.1080/004982597240073. PMID: 9381731. 2: Hansen KT, Stentoft K. Characterization of benzazepine UDP-glucuronosyl- transferases in laboratory animals and man. Xenobiotica. 1995 Jun;25(6):611-22. doi: 10.3109/00498259509061879. PMID: 7483661. 3: Hagelberg N, Forssell H, Aalto S, Rinne JO, Scheinin H, Taiminen T, Någren K, Eskola O, Jääskeläinen SK. Altered dopamine D2 receptor binding in atypical facial pain. Pain. 2003 Nov;106(1-2):43-8. doi: 10.1016/s0304-3959(03)00275-6. PMID: 14581109. 4: Hagelberg N, Forssell H, Rinne JO, Scheinin H, Taiminen T, Aalto S, Luutonen S, Någren K, Jääskeläinen S. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain. 2003 Jan;101(1-2):149-54. doi: 10.1016/s0304-3959(02)00323-8. PMID: 12507709. 5: Pascoe PJ, Taylor PM. Effects of dopamine antagonists on alfentanil-induced locomotor activity in horses. Vet Anaesth Analg. 2003 Jul;30(3):165-71. doi: 10.1046/j.1467-2995.2003.00134.x. PMID: 14498848. 6: Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):45-52. doi: 10.1016/0014-2999(92)90578-r. PMID: 1397049. 7: Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea- Ponce Y, Lombardo I, Van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 1999 May;32(2):93-109. doi: 10.1002/(SICI)1098-2396(199905)32:2<93::AID-SYN3>3.0.CO;2-C. PMID: 10231129. 8: Laihinen AO, Rinne JO, Ruottinen HM, Någren KA, Lehikoinen PK, Oikonen VJ, Ruotsalainen UH, Rinne UK. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J Nucl Med. 1994 Dec;35(12):1916-20. PMID: 7989969. 9: Peacock L, Hansen L, Mørkeberg F, Gerlach J. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects. Neuropsychopharmacology. 1999 Jan;20(1):35-43. doi: 10.1016/S0893-133X(98)00049-9. PMID: 9885783. 10: Hansen KT, Thomsen KF, Bundgaard H. Glucuronidation of the dopamine D-1 receptor antagonists NNC 0756 and NNC 0772 in liver microsomes. Drug Metab Dispos. 1992 Mar-Apr;20(2):172-8. PMID: 1352206.